Efficacy and safety of once‐weekly oral trelagliptin switched from once‐daily dipeptidyl peptidase‐4 inhibitor in patients with type 2 diabetes mellitus: An open‐label, phase 3 exploratory study

INTRODUCTION: Trelagliptin, a novel once‐weekly oral dipeptidyl peptidase‐4 (DPP‐4) inhibitor, has shown favorable efficacy and safety in type 2 diabetes mellitus patients. Trelagliptin was launched in Japan, and is expected to be initially used for switchover from a daily DPP‐4 inhibitor in the cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Inagaki, Nobuya, Sano, Hiroki, Seki, Yoshifumi, Kuroda, Shingo, Kaku, Kohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835476/
https://www.ncbi.nlm.nih.gov/pubmed/28836351
http://dx.doi.org/10.1111/jdi.12730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835476/
https://www.ncbi.nlm.nih.gov/pubmed/28836351
http://dx.doi.org/10.1111/jdi.12730

Ejemplares similares